ISSM Announces "2-For-1" Membership Promotion for New Members in China
For Some Men, Testosterone Therapy Might Lower Cardiovascular Risk
Health professionals who live or work and China may be eligible for a "2-For-1" membership program. Get two years of ISSM membership for the price of one!
Please note that the following terms and conditions apply:
• The promotion applies only to health professionals living or working in China.
• Only those who have never been an ISSM member or those who have terminated their ISSM membership in good standing (no unpaid fees) and have not been an ISSM member for at least two years can apply for the ISSM “2 for 1” membership promotion.
• The promotion is valid for new applications received from May 1, 2016 until September 30, 2016.
• All ISSM membership benefits will apply from the moment you become a member until December 31, 2017.
• Membership dues are payable for the first year on admission to membership (2016) and waived for the second year (2017). Starting in 2018, dues are payable annually.
• Any person eligible for membership will be admitted only on the approval of the Board of Directors.
It's easy to apply for membership! Get all the details here.
Testosterone replacement therapy may have protective effects for older men with both low testosterone and coronary artery disease, according to a new study.
Researchers from the Intermountain Medical Center Heart Institute in Salt Lake City, USA presented these findings at the American College of Cardiology's 65th Annual Scientific Session in Chicago last month.
Seven hundred fifty-five men with low testosterone and coronary artery disease participated in the study. Their age range was 58 to 78 years.
The men were divided into three groups. One group received high doses of testosterone (injection or gel), another received medium doses, and the third received no testosterone at all.
At one- and three-year follow-up points, the men who did not take testosterone were more likely to have major adverse cardiovascular events, such as heart attack, stroke, or death, than the other two groups.
Men in the high-dose testosterone group were the least likely to have such events.
Clinicians should not be changing their treatment protocols, however. More research is still needed, the authors said.
Learn more about this study.